Morgans has placed a hold recommendation on infant formula and organic baby food company Bubs Australia Ltd (ASX: BUB) as its shares take a dive down 7.2% to 83c at the time of writing.
Bubs has recently logged a number of new supply agreements with distributors in China’s off-line and online sales channels, most notably a partnership with QianJiaWanPu Co – a licensed manufacturer which will allow it to commence its CFDA application for its China-labelled infant formula products.
Bubs shares were placed in a voluntary trading halt on June 14 pending a company announcement and today reported a successful capital raising of $40 million at 75c per share.
Morgans has an 82c per share price target on the stock with an upgrade to its FY19/20 forecasts by 3.2% and 12.5% respectively off the back of new contract activity with the comment that Bubs management is making “solid progress” and “building a sustainable business”.
We’re living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.
That’s why at The Motley Fool we’ve been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Cochlear or REA Group.
We’ve found three exciting companies that we believe re poised to perform in the new year. Click here to uncover these ideas!
Motley Fool contributor Carin Pickworth has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of A2 Milk. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.